Search

Your search keyword '"Blach S"' showing total 140 results
Start Over Author "Blach S"
140 results on '"Blach S"'

1. Global reporting of progress towards elimination of hepatitis B and hepatitis C

Author

Cui, F, Blach, S, Manzengo Mingiedi, C, Gonzalez, MA, Sabry Alaama, A, Mozalevskis, A, Séguy, N, Rewari, BB, Chan, P-L, Le, L-V, Doherty, M, Luhmann, N, Easterbrook, P, Dirac, M, De Martel, C, Nayagam, S, Hallett, TB, Vickerman, P, Razavi, H, Lesi, O, and Low-Beer, D

Subjects
Hepatology, Gastroenterology
Abstract

BACKGROUND: The 69th World Health Assembly endorsed the global health sector strategy on viral hepatitis to eliminate viral hepatitis as a public health threat by 2030. Achieving and measuring the 2030 targets requires a substantial increase in the capacity to test and treat viral hepatitis infections and a mechanism to monitor the progress of hepatitis elimination. This study aimed to identify the gaps in data availability or quality and create a new mechanism to monitor the progress of hepatitis elimination. METHODS: In 2020, using a questionnaire, we collected empirical, systematic, modelled, or surveyed data-reported by WHO country and WHO regional offices-on indicators of progress towards elimination of viral hepatitis, including burden of infection, incidence, mortality, and the cascade of care, and validated these data. FINDINGS: WHO received officially validated country-provided data from 130 countries or territories, and used partner-provided data for 70 countries or territories. We estimated that in 2019, globally, 295·9 million (3·8%) people were living with chronic hepatitis B virus (HBV) infection and 57·8 million (0·8%) people were living with chronic hepatitis C virus (HCV) infection. Globally, there were more than 3·0 million new infections with HBV and HCV and more than 1·1 million deaths due to the viruses in 2019. In 2019, 30·4 million (95% CI 24·3-38·0) individuals living with hepatitis B knew their infection status and 6·6 million (5·3-8·3) people diagnosed with hepatitis B received treatment. Among people with HCV infection, 15·2 million (95% CI 12·1-19·0) had been diagnosed between 2015 and 2019, and 9·4 million (7·5-11·7) people diagnosed with hepatitis C infection were treated with direct-acting antiviral drugs between 2015 and 2019. INTERPRETATION: There has been notable global progress towards hepatitis elimination. In 2019, 30·4 million (10·3%) people living with hepatitis B knew their infection status, which was slightly higher than in 2015 (22·0 million; 9·0%), and 6·6 million (22·7%) of those diagnosed with hepatitis B received treatment, compared with 1·7 million (8·0%) in 2015. Mortality from hepatitis C has declined since 2019, driven by an increase in HCV treatment ten times that of the strategy baseline. However, an estimated 89·7% of HBV infections and 78·6% of HCV infections remain undiagnosed. A new global strategy for 2022-30, based on these new estimates, should be implemented urgently to scale up the screening and treatment of viral hepatitis. FUNDING: World Health Organization.

Published
2023

2. Strategies to manage hepatitis C virus infection disease burden—Volume 4

Author

Chen, D. S., Hamoudi, W., Mustapha, B., Layden, J., Nersesov, A., Reic, T., Garcia, V., Rios, C., Mateva, L., Njoya, O., Al‐Busafi, S. A., Abdelmageed, M. K., Abdulla, M., Adda, D., Akin, O., Al Baqali, A., Al Dweik, N., Al Ejji, K., Al ghazzawi, I., Al Kaabi, S., Al Naamani, K., Al Qamish, J., Al Sadadi, M., Al Salman, J., AlBadri, M., Al‐Romaihi, H. E., Ampofo, W., Antonov, K., Anyaike, C., Arome, F., Bane, A., Blach, S., Borodo, M. M., Brandon, S. M., Bright, B., Butt, M. T., Cardenas, I., Chan, H. L. Y., Chen, C. J., Chen, P. J., Chien, R. N., Chuang, W. L., Cuellar, D., Derbala, M., Elbardiny, A. A., Estes, C., Farag, E., Fung, J., Gamkrelidze, I., Genov, J., Ghandour, Z., Ghuloom, M., Gomez, B., Gunter, J., Habeeb, J., Hajelssedig, O., Himatt, S. M., Hrstic, I., Hu, C. C., Huang, C. F., Hui, Y. T., Jahis, R., Jelev, D., John, A. K., Kaliaskarova, K. S., Kamel, Y., Kao, J. H., Khamis, J., Khattabi, H., Khoudri, I., Konysbekova, A., Kotzev, I., Lai, M. S., Lao, W. C., Lee, M. H., Lesi, O., Li, M., Lo, A., Loo, C. K., Lukšić, B., Maaroufi, A., Malu, A. O., Mitova, R., Mohamed, R., Morović, M., Murphy, K., Nde, H., Ngige, E., Njouom, R., Nonković, D., Obekpa, S., Oguche, S., Okolo, E. E., Omede, O., Omuemu, C., Ondoa, P., Opare‐Sem, O., Owusu‐Ofori, S., Phillips, R. O., Prokopenko, Y. N., Razavi, H., Razavi‐Shearer, D., Razavi‐Shearer, K., Redae, B., Rinke de Wit, T., Robbins, S., Roberts, L. R., Sanad, S. J., Sharma, M., Simonova, M., Su, T. H., Sultan, K., Tan, S. S., Tchernev, K., Tsang, O. T. Y., Tsang, S., Tzeuton, C., Ugoeze, S., Uzochukwu, B., Vi, R., Vince, A., Wani, H. U., Wong, V. W. S., Workneh, A., Yacoub, R., Yesmembetov, K. I., Youbi, M., Yuen, M. F., and Schmelzer, J. D.

Published
2017
Full Text
View/download PDF

3. The present and future disease burden of hepatitis C virus infections with todayʼs treatment paradigm: Volume 4

Author

Chan, H. L. Y., Chen, C. J., Omede, O., Al Qamish, J., Al Naamani, K., Bane, A., Tan, S. S., Simonova, M., Cardenas, I., Derbala, M., Akin, O., Phillips, R. O., Abdelmageed, M. K., Abdulla, M., Adda, D., Al Baqali, A., Al Dweik, N., Al Ejji, K., Al ghazzawi, I., Al Kaabi, S., Al Sadadi, M., Al Salman, J., AlBadri, M., Al‐Busafi, S. A., Al‐Romaihi, H. E., Ampofo, W., Antonov, K., Anyaike, C., Arome, F., Blach, S., Borodo, M. M., Brandon, S. M., Bright, B., Butt, M. T., Chen, D. S., Chen, P. J., Chien, R. N., Chuang, W. L., Cuellar, D., Elbardiny, A. A., Estes, C., Farag, E., Fung, J., Gamkrelidze, I., Garcia, V., Genov, J., Ghandour, Z., Ghuloom, M., Gomez, B., Gunter, J., Habeeb, J., Hajelssedig, O., Hamoudi, W., Himatt, S. M., Hrstic, I., Hu, C. C., Huang, C. F., Hui, Y. T., Jahis, R., Jelev, D., John, A. K., Kaliaskarova, K. S., Kamel, Y., Kao, J. H., Khamis, J., Khattabi, H., Khoudri, I., Konysbekova, A., Kotzev, I., Lai, M. S., Lao, W. C., Layden, J., Lee, M. H., Lesi, O., Li, M., Lo, A., Loo, C. K., Lukšić, B., Maaroufi, A., Malu, A. O., Mateva, L., Mitova, R., Mohamed, R., Morović, M., Murphy, K., Mustapha, B., Nersesov, A., Ngige, E., Njouom, R., Njoya, O., Nonković, D., Obekpa, S., Oguche, S., Okolo, E. E., Omuemu, C., Ondoa, P., Opare‐Sem, O., Owusu‐Ofori, S., Prokopenko, Y. N., Razavi, H., Razavi‐Shearer, D., Razavi‐Shearer, K., Redae, B., Reic, T., Rinke de Wit, T., Rios, C., Robbins, S., Roberts, L. R., Sanad, S. J., Schmelzer, J. D., Sharma, M., Su, T. H., Sultan, K., Tchernev, K., Tsang, O. T. Y., Tsang, S., Tzeuton, C., Ugoeze, S., Uzochukwu, B., Vi, R., Vince, A., Wani, H. U., Wong, V. W. S., Workneh, A., Yacoub, R., Yesmembetov, K. I., Youbi, M., Yuen, M. F., and Nde, H.

Published
2017
Full Text
View/download PDF

4. Historical epidemiology of hepatitis C virus in select countries—volume 4

Author

Maaroufi, A., Vince, A., Himatt, S. M., Mohamed, R., Fung, J., Opare‐Sem, O., Workneh, A., Njouom, R., Al ghazzawi, I., Abdulla, M., Kaliaskarova, K. S., Owusu‐Ofori, S., Abdelmageed, M. K., Adda, D., Akin, O., Al Baqali, A., Al Dweik, N., Al Ejji, K., Al Kaabi, S., Al Naamani, K., Al Qamish, J., Al Sadadi, M., Al Salman, J., AlBadri, M., Al‐Busafi, S. A., Al‐Romaihi, H. E., Ampofo, W., Antonov, K., Anyaike, C., Arome, F., Bane, A., Blach, S., Borodo, M. M., Brandon, S. M., Bright, B., Butt, M. T., Cardenas, I., Chan, H. L. Y., Chen, C. J., Chen, D. S., Chen, P. J., Chien, R. N., Chuang, W. L., Cuellar, D., Derbala, M., Elbardiny, A. A., Estes, C., Farag, E., Gamkrelidze, I., Garcia, V., Genov, J., Ghandour, Z., Ghuloom, M., Gomez, B., Gunter, J., Habeeb, J., Hajelssedig, O., Hamoudi, W., Hrstic, I., Hu, C. C., Huang, C. F., Hui, Y. T., Jahis, R., Jelev, D., John, A. K., Kamel, Y., Kao, J. H., Khamis, J., Khattabi, H., Khoudri, I., Konysbekova, A., Kotzev, I., Lai, M. S., Lao, W. C., Layden, J., Lee, M. H., Lesi, O., Li, M., Lo, A., Loo, C. K., Lukšić, B., Malu, A. O., Mateva, L., Mitova, R., Morović, M., Murphy, K., Mustapha, B., Nde, H., Nersesov, A., Ngige, E., Njoya, O., Nonković, D., Obekpa, S., Oguche, S., Okolo, E. E., Omede, O., Omuemu, C., Ondoa, P., Phillips, R. O., Prokopenko, Y. N., Razavi, H., Razavi‐Shearer, D., Redae, B., Reic, T., Rinke de Wit, T., Rios, C., Robbins, S., Roberts, L. R., Sanad, S. J., Schmelzer, J. D., Sharma, M., Simonova, M., Su, T. H., Sultan, K., Tan, S. S., Tchernev, K., Tsang, O. T. Y., Tsang, S., Tzeuton, C., Ugoeze, S., Uzochukwu, B., Vi, R., Wani, H. U., Wong, V. W. S., Yacoub, R., Yesmembetov, K. I., Youbi, M., Yuen, M. F., and Razavi‐Shearer, K.

Published
2017
Full Text
View/download PDF

6. Optimization of hepatitis C virus screening strategies by birth cohort in Italy

Author

Kondili L. A., Gamkrelidze I., Blach S., Marcellusi A., Galli M., Petta S., Puoti M., Vella S., Razavi H., Craxi A., Mennini F. S., on behalf of PITER collaborating group, Federico A., Dallio M., Loguercio C., A Kondili, L, Gamkrelidze, I, Blach, S, Marcellusi, A, Galli, M, Petta, S, Puoti, M, Vella, S, Razavi, H, Craxi, A, S Mennini, F, collaborating group, P, Kondili L.A., Gamkrelidze I., Blach S., Marcellusi A., Galli M., Petta S., Puoti M., Vella S., Razavi H., Craxi A., Mennini F.S., Kondili, L. A., Gamkrelidze, I., Blach, S., Marcellusi, A., Galli, M., Petta, S., Puoti, M., Vella, S., Razavi, H., Craxi, A., Mennini, F. S., on behalf of PITER collaborating, Group, Federico, A., Dallio, M., and Loguercio, C.

Subjects
medicine.medical_specialty, Cost effectiveness, Cost-Benefit Analysis, Hepatitis C virus, Settore SECS-P/06, cost-effectivene, Hepacivirus, medicine.disease_cause, Antiviral Agents, World health, NO, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, Mass Screening, cost-effectiveness, Antibody screens, Hepatology, Under-five, business.industry, screening, Health services research, health, cost‐effectiveness, Hepatitis C, Chronic, Hepatitis C, Italy, 030220 oncology & carcinogenesis, Settore MED/42, HCV, Original Article, epidemiology, 030211 gastroenterology & hepatology, Liver Disease and Public Health, Quality-Adjusted Life Years, Birth cohort, business, WHO targets, cost-effectiveness, HCV, screening, WHO targets, Demography
Abstract

Background and Aims Cost‐effective screening strategies are needed to make hepatitis C virus (HCV) elimination a reality. We determined if birth cohort screening is cost‐effective in Italy. Methods A model was developed to quantify screening and healthcare costs associated with HCV. The model‐estimated prevalence of undiagnosed HCV was used to calculate the antibody screens needed annually, with a €25 000 cost‐effectiveness threshold. Outcomes were assessed under the status quo and a scenario that met the World Health Organization's targets for elimination of HCV. The elimination scenario was assessed under five screening strategies. Results A graduated birth cohort screening strategy (graduated screening 1: 1968‐1987 birth cohorts, then expanding to 1948‐1967 cohorts) was the least costly. This strategy would gain approximately 144 000 quality‐adjusted life years (QALYs) by 2031 and result in an 89.3% reduction in HCV cases, compared to an 89.6%, 89.0%, 89.7% and 88.7% reduction for inversed graduated screening, 1948‐77 birth cohort, 1958‐77 birth cohort and universal screening, respectively. Graduated screening 1 yielded the lowest incremental cost‐effectiveness ratio (ICER) of €3552 per QALY gained. Conclusions In Italy, a graduated screening scenario is the most cost‐effective strategy. Other countries could consider a similar birth cohort approach when developing HCV screening strategies., See Editorial on Page 1538

Published
2020

7. The present and future disease burden of hepatitis C virus infections with todayʼs treatment paradigm – volume 3

Author

Sibley, A., Han, K. H., Abourached, A., Lesmana, L. A., Makara, M., Jafri, W., Salupere, R., Assiri, A. M., Goldis, A., Abaalkhail, F., Abbas, Z., Abdou, A., Al Braiki, F., Al Hosani, F., Al Jaberi, K., Al Khatry, M., Al Mulla, M. A., Al Quraishi, H., Al Rifai, A., Al Serkal, Y., Alam, A., Alavian, S. M., Alashgar, H. I., Alawadhi, S., Al-Dabal, L., Aldins, P., Alfaleh, F. Z., Alghamdi, A. S., Al-Hakeem, R., Aljumah, A. A., Almessabi, A., Alqutub, A. N., Alswat, K. A., Altraif, I., Alzaabi, M., Andrea, N., Babatin, M. A., Baqir, A., Barakat, M. T., Bergmann, O. M., Bizri, A. R., Blach, S., Chaudhry, A., Choi, M. S., Diab, T., Djauzi, S., El Hassan, E. S., El Khoury, S., Estes, C., Fakhry, S., Farooqi, J. I., Fridjonsdottir, H., Gani, R. A., Ghafoor Khan, A., Gheorghe, L., Gottfredsson, M., Gregorcic, S., Gunter, J., Hajarizadeh, B., Hamid, S., Hasan, I., Hashim, A., Horvath, G., Hunyady, B., Husni, R., Jeruma, A., Jonasson, J. G., Karlsdottir, B., Kim, D. Y., Kim, Y. S., Koutoubi, Z., Liakina, V., Lim, Y. S., Löve, A., Maimets, M., Malekzadeh, R., Matičič, M., Memon, M. S., Merat, S., Mokhbat, J. E., Mourad, F. H., Muljono, D. H., Nawaz, A., Nugrahini, N., Olafsson, S., Priohutomo, S., Qureshi, H., Rassam, P., Razavi, H., Razavi-Shearer, D., Razavi-Shearer, K., Rozentale, B., Sadik, M., Saeed, K., Salamat, A., Sanai, F. M., Sanityoso Sulaiman, A., Sayegh, R. A., Sharara, A. I., Siddiq, M., Siddiqui, A. M., Sigmundsdottir, G., Sigurdardottir, B., Speiciene, D., Sulaiman, A., Sultan, M. A., Taha, M., Tanaka, J., Tarifi, H., Tayyab, G., Tolmane, I., Ud din, M., Umar, M., Valantinas, J., Videčnik-Zorman, J., Yaghi, C., Yunihastuti, E., Yusuf, M. A., Zuberi, B. F., and Schmelzer, J. D.

Published
2015
Full Text
View/download PDF

8. Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 3

Author

Liakina, V., Hamid, S., Tanaka, J., Olafsson, S., Sharara, A. I., Alavian, S. M., Gheorghe, L., El Hassan, E. S., Abaalkhail, F., Abbas, Z., Abdou, A., Abourached, A., Al Braiki, F., Al Hosani, F., Al Jaberi, K., Al Khatry, M., Al Mulla, M. A., Al Quraishi, H., Al Rifai, A., Al Serkal, Y., Alam, A., Alashgar, H. I., Alawadhi, S., Al-Dabal, L., Aldins, P., Alfaleh, F. Z., Alghamdi, A. S., Al-Hakeem, R., Aljumah, A. A., Almessabi, A., Alqutub, A. N., Alswat, K. A., Altraif, I., Alzaabi, M., Andrea, N., Assiri, A. M., Babatin, M. A., Baqir, A., Barakat, M. T., Bergmann, O. M., Bizri, A. R., Blach, S., Chaudhry, A., Choi, M. S., Diab, T., Djauzi, S., El Khoury, S., Estes, C., Fakhry, S., Farooqi, J. I., Fridjonsdottir, H., Gani, R. A., Ghafoor Khan, A., Goldis, A., Gottfredsson, M., Gregorcic, S., Hajarizadeh, B., Han, K. H., Hasan, I., Hashim, A., Horvath, G., Hunyady, B., Husni, R., Jafri, W., Jeruma, A., Jonasson, J. G., Karlsdottir, B., Kim, D. Y., Kim, Y. S., Koutoubi, Z., Lesmana, L. A., Lim, Y. S., Löve, A., Maimets, M., Makara, M., Malekzadeh, R., Matičič, M., Memon, M. S., Merat, S., Mokhbat, J. E., Mourad, F. H., Muljono, D. H., Nawaz, A., Nugrahini, N., Priohutomo, S., Qureshi, H., Rassam, P., Razavi, H., Razavi-Shearer, D., Razavi-Shearer, K., Rozentale, B., Sadik, M., Saeed, K., Salamat, A., Salupere, R., Sanai, F. M., Sanityoso Sulaiman, A., Sayegh, R. A., Schmelzer, J. D., Sibley, A., Siddiq, M., Siddiqui, A. M., Sigmundsdottir, G., Sigurdardottir, B., Speiciene, D., Sulaiman, A., Sultan, M. A., Taha, M., Tarifi, H., Tayyab, G., Tolmane, I., Ud din, M., Umar, M., Valantinas, J., Videčnik-Zorman, J., Yaghi, C., Yunihastuti, E., Yusuf, M. A., Zuberi, B. F., and Gunter, J.

Published
2015
Full Text
View/download PDF

9. Strategies to manage hepatitis C virus infection disease burden – volume 3

Author

Alfaleh, F. Z., Nugrahini, N., Matičič, M., Tolmane, I., Alzaabi, M., Hajarizadeh, B., Valantinas, J., Kim, D. Y., Hunyady, B., Abaalkhail, F., Abbas, Z., Abdou, A., Abourached, A., Al Braiki, F., Al Hosani, F., Al Jaberi, K., Al Khatry, M., Al Mulla, M. A., Al Quraishi, H., Al Rifai, A., Al Serkal, Y., Alam, A., Alashgar, H. I., Alavian, S. M., Alawadhi, S., Al-Dabal, L., Aldins, P., Alghamdi, A. S., Al-Hakeem, R., Aljumah, A. A., Almessabi, A., Alqutub, A. N., Alswat, K. A., Altraif, I., Andrea, N., Assiri, A. M., Babatin, M. A., Baqir, A., Barakat, M. T., Bergmann, O. M., Bizri, A. R., Chaudhry, A., Choi, M. S., Diab, T., Djauzi, S., El Hassan, E. S., El Khoury, S., Estes, C., Fakhry, S., Farooqi, J. I., Fridjonsdottir, H., Gani, R. A., Ghafoor Khan, A., Gheorghe, L., Goldis, A., Gottfredsson, M., Gregorcic, S., Gunter, J., Hamid, S., Han, K. H., Hasan, I., Hashim, A., Horvath, G., Husni, R., Jafri, W., Jeruma, A., Jonasson, J. G., Karlsdottir, B., Kim, Y. S., Koutoubi, Z., Lesmana, L. A., Liakina, V., Lim, Y. S., Löve, A., Maimets, M., Makara, M., Malekzadeh, R., Memon, M. S., Merat, S., Mokhbat, J. E., Mourad, F. H., Muljono, D. H., Nawaz, A., Olafsson, S., Priohutomo, S., Qureshi, H., Rassam, P., Razavi, H., Razavi-Shearer, D., Razavi-Shearer, K., Rozentale, B., Sadik, M., Saeed, K., Salamat, A., Salupere, R., Sanai, F. M., Sanityoso Sulaiman, A., Sayegh, R. A., Schmelzer, J. D., Sharara, A. I., Sibley, A., Siddiq, M., Siddiqui, A. M., Sigmundsdottir, G., Sigurdardottir, B., Speiciene, D., Sulaiman, A., Sultan, M. A., Taha, M., Tanaka, J., Tarifi, H., Tayyab, G., Ud din, M., Umar, M., Videčnik-Zorman, J., Yaghi, C., Yunihastuti, E., Yusuf, M. A., Zuberi, B. F., and Blach, S.

Published
2015
Full Text
View/download PDF

10. The present and future disease burden of hepatitis C virus (HCV) infections with todayʼs treatment paradigm – volume 2

Author

Hatzakis, A., Chulanov, V., Gadano, A. C., Bergin, C., Ben-Ari, Z., Mossong, J., Schréter, I., Baatarkhuu, O., Acharya, S., Aho, I., Anand, A. C., Andersson, M. I., Arendt, V., Arkkila, P., Barclay, K., Bessone, F., Blach, S., Blokhina, N., Brunton, C. R., Choudhuri, G., Cisneros, L., Croes, E. A., Dahgwahdorj, Y. A., Dalgard, O., Daruich, J. R., Dashdorj, N. R., Davaadorj, D., de Knegt, R. J., de Vree, M., Estes, C., Flisiak, R., Gane, E., Gower, E., Halota, W., Henderson, C., Hoffmann, P., Hornell, J., Houlihan, D., Hrusovsky, S., Jarčuška, P., Kershenobich, D., Kostrzewska, K., Kristian, P., Leshno, M., Lurie, Y., Mahomed, A., Mamonova, N., Mendez-Sanchez, N., Norris, S., Nurmukhametova, E., Nymadawa, P., Oltman, M., Oyunbileg, J., Oyunsuren, Ts., Papatheodoridis, G., Pimenov, N., Prabdial-Sing, N., Prins, M., Radke, S., Rakhmanova, A., Razavi-Shearer, K., Reesink, H. W., Ridruejo, E., Safadi, R., Sagalova, O., Avila, Sanchez J. F., Sanduijav, R., Saraswat, V., Seguin-Devaux, C., Shah, S. R., Shestakova, I., Shevaldin, A., Shibolet, O., Silva, M. O., Sokolov, S., Sonderup, M., Souliotis, K., Spearman, C. W., Staub, T., Stedman, C., Strebkova, E. A., Struck, D., Sypsa, V., Tomasiewicz, K., Undram, L., van der Meer, A. J., van Santen, D., Veldhuijzen, I., Villamil, F. G., Willemse, S., Zuckerman, E., Zuure, F. R., Puri, P., and Razavi, H.

Published
2015
Full Text
View/download PDF

11. Strategies to manage hepatitis C virus (HCV) infection disease burden – volume 2

Author

Gane, E., Kershenobich, D., Seguin-Devaux, C., Kristian, P., Aho, I., Dalgard, O., Shestakova, I., Nymadawa, P., Blach, S., Acharya, S., Anand, A. C., Andersson, M. I., Arendt, V., Arkkila, P., Baatarkhuu, O., Barclay, K., Ben-Ari, Z., Bergin, C., Bessone, F., Blokhina, N., Brunton, C. R., Choudhuri, G., Chulanov, V., Cisneros, L., Croes, E. A., Dahgwahdorj, Y. A., Daruich, J. R., Dashdorj, N. R., Davaadorj, D., de Knegt, R. J., de Vree, M., Gadano, A. C., Gower, E., Halota, W., Hatzakis, A., Henderson, C., Hoffmann, P., Hornell, J., Houlihan, D., Hrusovsky, S., Jarčuška, P., Kostrzewska, K., Leshno, M., Lurie, Y., Mahomed, A., Mamonova, N., Mendez-Sanchez, N., Mossong, J., Norris, S., Nurmukhametova, E., Oltman, M., Oyunbileg, J., Oyunsuren, Ts., Papatheodoridis, G., Pimenov, N., Prins, M., Puri, P., Radke, S., Rakhmanova, A., Razavi, H., Razavi-Shearer, K., Reesink, H. W., Ridruejo, E., Safadi, R., Sagalova, O., Avila, Sanchez J. F., Sanduijav, R., Saraswat, V., Schréter, I., Shah, S. R., Shevaldin, A., Shibolet, O., Silva, M. O., Sokolov, S., Sonderup, M., Souliotis, K., Spearman, C. W., Staub, T., Stedman, C., Strebkova, E. A., Struck, D., Sypsa, V., Tomasiewicz, K., Undram, L., van der Meer, A. J., van Santen, D., Veldhuijzen, I., Villamil, F. G., Willemse, S., Zuckerman, E., Zuure, F. R., Prabdial-Sing, N., Flisiak, R., and Estes, C.

Published
2015
Full Text
View/download PDF

12. Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 2

Author

Saraswat, V., Norris, S., de Knegt, R. J., Avila, Sanchez J. F., Sonderup, M., Zuckerman, E., Arkkila, P., Stedman, C., Acharya, S., Aho, I., Anand, A. C., Andersson, M. I., Arendt, V., Baatarkhuu, O., Barclay, K., Ben-Ari, Z., Bergin, C., Bessone, F., Blach, S., Blokhina, N., Brunton, C. R., Choudhuri, G., Chulanov, V., Cisneros, L., Croes, E. A., Dahgwahdorj, Y. A., Dalgard, O., Daruich, J. R., Dashdorj, N. R., Davaadorj, D., de Vree, M., Estes, C., Flisiak, R., Gadano, A. C., Gane, E., Halota, W., Hatzakis, A., Henderson, C., Hoffmann, P., Hornell, J., Houlihan, D., Hrusovsky, S., Jarčuška, P., Kershenobich, D., Kostrzewska, K., Kristian, P., Leshno, M., Lurie, Y., Mahomed, A., Mamonova, N., Mendez-Sanchez, N., Mossong, J., Nurmukhametova, E., Nymadawa, P., Oltman, M., Oyunbileg, J., Oyunsuren, Ts., Papatheodoridis, G., Pimenov, N., Prabdial-Sing, N., Prins, M., Puri, P., Radke, S., Rakhmanova, A., Razavi, H., Razavi-Shearer, K., Reesink, H. W., Ridruejo, E., Safadi, R., Sagalova, O., Sanduijav, R., Schréter, I., Seguin-Devaux, C., Shah, S. R., Shestakova, I., Shevaldin, A., Shibolet, O., Sokolov, S., Souliotis, K., Spearman, C. W., Staub, T., Strebkova, E. A., Struck, D., Tomasiewicz, K., Undram, L., van der Meer, A. J., van Santen, D., Veldhuijzen, I., Villamil, F. G., Willemse, S., Zuure, F. R., Silva, M. O., Sypsa, V., and Gower, E.

Published
2015
Full Text
View/download PDF

13. The case for simplifying and using absolute targets for viral hepatitis elimination goals

Author

Razavi, H. Blach, S. Razavi-Shearer, D. Abaalkhail, F. Abbas, Z. Abdallah, A. Abrao Ferreira, P. Abu Raddad, L.J. Adda, D. Agarwal, K. Aghemo, A. Ahmed, A. Al-Busafi, S.A. Al-hamoudi, W. Al-Kaabi, S. Al-Romaihi, H. Aljarallah, B. AlNaamani, K. Alqahtani, S. Alswat, K. Altraif, I. Asselah, T. Bacon, B. Bessone, F. Bizri, A.R. Block, T. Bonino, F. Brandão-Mello, C.E. Brown, K. Bruggmann, P. Brunetto, M.R. Buti, M. Cabezas, J. Calleja, J.L. Castro Batänjer, E. Chan, H.L.-Y. Chang, H. Chen, C.-J. Christensen, P.B. Chuang, W.-L. Cisneros, L. Cohen, C. Colombo, M. Conway, B. Cooper, C. Craxi, A. Crespo, J. Croes, E. Cryer, D. Cupertino de Barros, F.P. Derbala, M. Dillon, J. Doss, W. Dou, X. Doyle, J. Duberg, A.-S. Dugan, E. Dunn, R. Dusheiko, G. El Khayat, H. El-Sayed, M.H. Eshraghian, A. Esmat, G. Esteban Mur, R. Ezzat, S. Falconer, K. Fassio, E. Ferrinho, P. Flamm, S. Flisiak, R. Foster, G. Fung, J. García-Samaniego, J. Gish, R.G. Gonçales, F. Halota, W. Hamoudi, W. Hassany, M. Hatzakis, A. Hay, S. Himatt, S. Hoepelman, I.M. Hsu, Y.-C. Hui, Y.T. Hunyady, B. Jacobson, I. Janjua, N. Janssen, H. Jarcuska, P. Kabagambe, K. Kanto, T. Kao, J.-H. Kaymakoglu, S. Kershenobich, D. Khamis, F. Kim, D.J. Kim, D.Y. Kondili, L.A. Kottilil, S. Kramvis, A. Kugelmas, M. Kurosaki, M. Lacombe, K. Lagging, M. Lao, W.-C. Lavanchy, D. Lazarus, J.V. Lee, A. Lee, S.S. Levy, M. Liakina, V. Lim, Y.-S. Liu, S. Maddrey, W. Malekzadeh, R. Marinho, R.T. Mathur, P. Maticic, M. Mendes Correa, M.C. Mera, J. Merat, S. Mogawer, S. Mohamed, R. Muellhaupt, B. Muljono, D. Mostafa, I. Nahum, M.S. Nawaz, A. Negro, F. Ninburg, M. Ning, Q. Ntiri- Reid, B. Nymadawa, P. Oevrehus, A. Ormeci, N. Orrego, M. Osman, A. Oyunsuren, T. Pan, C. Papaevangelou, V. Papatheodoridis, G. Popping, S. Prasad, P. Prithiviputh, R. Qureshi, H. Ramji, A. Razavi-Shearer, K. Reddy, R. Remak, W. Richter, C. Ridruejo, E. Robaeys, G. Roberts, S. Roberts, L. Roudot-Thoraval, F. Saab, S. Said, S. Salamat, A. Sanai, F. Sanchez-Avila, J.F. Schiff, E. Schinazi, R. Sebastiani, G. Seguin-Devaux, C. Shanmugam, R.P. Sharara, A. Shilton, S. Shouval, D. Sievert, W. Simonova, M. Sohrabpour, A.A. Sonderup, M. Soza, A. Wendy Spearman, C. Steinfurth, N. Sulkowski, M. Tan, S.-S. Tanaka, J. Tashi, D. Thein, H.-H. Thompson, P. Tolmane, I. Toy, M. Valantinas, J. Van de Vijver, D. Vélez-Möller, P. Vince, A. Waked, I. Wang, S. Wedemeyer, H. Wong, V. Xie, Q. Yamada, S. Yang, H.-I. Yesmembetov, K. Yilmaz, Y. Younossi, Z. Yu, M.-L. Yuen, M.-F. Yurdaydin, C. Yusuf, A. Zekry, A. Zeuzem, S. Polaris Observatory Collaborators

Subjects
digestive system diseases
Abstract

The 69th World Health Assembly endorsed the Global Health Sector Strategy for Viral Hepatitis, embracing a goal to eliminate hepatitis infection as a public health threat by 2030. This was followed by the World Health Organization's (WHO) global targets for the care and management of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. These announcements and targets were important in raising awareness and calling for action; however, tracking countries’ progress towards these elimination goals has provided insights to the limitations of these targets. The existing targets compare a country's progress relative to its 2015 values, penalizing countries who started their programmes prior to 2015, countries with a young population, or countries with a low prevalence. We recommend that (1) WHO simplify the hepatitis elimination targets, (2) change to absolute targets and (3) allow countries to achieve these disease targets with their own service coverage initiatives that will have the maximum impact. The recommended targets are as follows: reduce HCV new chronic cases to ≤5 per 100 000, reduce HBV prevalence among 1-year-olds to ≤0.1%, reduce HBV and HCV mortality to ≤5 per 100 000, and demonstrate HBV and HCV year-to-year decrease in new HCV- and HBV-related HCC cases. The objective of our recommendations is not to lower expectations or diminish the hepatitis elimination standards, but to provide clearer targets that recognize the past and current elimination efforts by countries, help measure progress towards true elimination, and motivate other countries to follow suit. © 2020 John Wiley & Sons Ltd

Published
2021

14. Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?

Author

Kondili, La, Robbins, S, Blach, S, Gamkrelidze, I, Zignego, Al, Brunetto, Mr, Raimondo, G, Taliani, G, Iannone, A, Russo, Fp, Santantonio, Ta, Zuin, M, Chessa, L, Blanc, P, Puoti, M, Vinci, M, Erne, Em, Strazzabosco, M, Massari, M, Lampertico, P, Rumi, Mg, Federico, A, Orlandini, A, Ciancio, A, Borgia, G, Andreone, P, Caporaso, N, Persico, M, Ieluzzi, D, Madonia, S, Gori, A, Gasbarrini, A, Coppola, C, Brancaccio, G, Andriulli, A, Quaranta, Mg, Montilla, S, Razavi, H, Melazzini, M, Vella, S, Craxì, A, PITER Collaborating, Group., Kondili LA, Robbins S, Blach S, Gamkrelidze I, Zignego AL, Brunetto MR, Raimondo G, Taliani G, Iannone A, Russo FP, Santantonio TA, Zuin M, Chessa L, Blanc P, Puoti M, Vinci M, Erne EM, Strazzabosco M, Massari M, Lampertico P, Rumi MG, Federico A, Orlandini A, Ciancio A, Borgia G, Andreone P, Caporaso N, Persico M, Ieluzzi D, Madonia S, Gori A, Gasbarrini A, Coppola C, Brancaccio G, Andriulli A, Quaranta MG, Montilla S, Razavi H, Melazzini M, Vella S, Craxì Antonio, Kondili, Loreta A., Robbins, Sarah, Blach, Sarah, Gamkrelidze, Ivane, Zignego, Anna L., Brunetto, Maurizia R., Raimondo, Giovanni, Taliani, Gloria, Iannone, Andrea, Russo, Francesco P., Santantonio, Teresa A., Zuin, Massimo, Chessa, Luchino, Blanc, Pierluigi, Puoti, Massimo, Vinci, Maria, Erne, Elke M., Strazzabosco, Mario, Massari, Marco, Lampertico, Pietro, Rumi, Maria G., Federico, Alessandro, Orlandini, Alessandra, Ciancio, Alessia, Borgia, Guglielmo, Andreone, Pietro, Caporaso, Nicola, Persico, Marcello, Ieluzzi, Donatella, Madonia, Salvatore, Gori, Andrea, Gasbarrini, Antonio, Coppola, Carmine, Brancaccio, Giuseppina, Andriulli, Angelo, Quaranta, Maria G., Montilla, Simona, Razavi, Homie, Melazzini, Mario, Vella, Stefano, Craxì, Antonio, Kondili, L. A., Robbins, S., Blach, S., Gamkrelidze, I., Zignego, A. L., Brunetto, M. R., Raimondo, G., Taliani, G., Iannone, A., Russo, F. P., Santantonio, T. A., Zuin, M., Chessa, L., Blanc, P., Puoti, M., Vinci, M., Erne, E. M., Strazzabosco, M., Massari, M., Lampertico, P., Rumi, M. G., Federico, A., Orlandini, A., Ciancio, A., Borgia, G., Andreone, P., Caporaso, N., Persico, M., Ieluzzi, D., Madonia, S., Gori, A., Gasbarrini, A., Coppola, C., Brancaccio, G., Andriulli, A., Quaranta, M. G., Montilla, S., Razavi, H., Melazzini, M., Vella, S., Craxi, A., Kondili, L, Robbins, S, Blach, S, Gamkrelidze, I, Zignego, A, Brunetto, M, Raimondo, G, Taliani, G, Iannone, A, Russo, F, Santantonio, T, Zuin, M, Chessa, L, Blanc, P, Puoti, M, Vinci, M, Erne, E, Strazzabosco, M, Massari, M, Lampertico, P, Rumi, M, Federico, A, Orlandini, A, Ciancio, A, Borgia, G, Andreone, P, Caporaso, N, Persico, M, Ieluzzi, D, Madonia, S, Gori, A, Gasbarrini, A, Coppola, C, Brancaccio, G, Andriulli, A, Quaranta, M, Montilla, S, Razavi, H, Melazzini, M, Vella, S, and Craxi, A

Subjects
HCV, WHO, chronic infection, linkage to care, Liver Cirrhosis, medicine.medical_specialty, Carcinoma, Hepatocellular, Sustained Virologic Response, Viral Hepatitis, Settore MED/12 - GASTROENTEROLOGIA, World Health Organization, Antiviral Agents, NO, 03 medical and health sciences, Liver disease, 0302 clinical medicine, Pharmacotherapy, Cost of Illness, Cause of Death, Health care, medicine, Humans, 030212 general & internal medicine, Viremia, chronic infection, HCV, linkage to care, WHO, Disease Eradication, Mortality, Intensive care medicine, Cause of death, Hepatology, business.industry, Public health, Carcinoma, Liver Neoplasms, Hepatocellular, Hepatitis C, medicine.disease, Markov Chains, Italy, 030211 gastroenterology & hepatology, business, Viral hepatitis
Abstract

Background & Aims Advances in direct‐acting antiviral treatment of HCV have reinvigorated public health initiatives aimed at identifying affected individuals. We evaluated the possible impact of only diagnosed and linked‐to‐care individuals on overall HCV burden estimates and identified a possible strategy to achieve the WHO targets by 2030. Methods Using a modelling approach grounded in Italian real‐life data of diagnosed and treated patients, different linkage‐to‐care scenarios were built to evaluate potential strategies in achieving the HCV elimination goals. Results Under the 40% linked‐to‐care scenario, viraemic burden would decline (60%); however, eligible patients to treat will be depleted by 2025. Increased case finding through a targeted screening strategy in 1948‐1978 birth cohorts could supplement the pool of diagnosed patients by finding 75% of F0‐F3 cases. Under the 60% linked‐to‐care scenario, viraemic infections would decline by 70% by 2030 but the patients eligible for treatment will run out by 2028. If treatment is to be maintained, a screening strategy focusing on 1958‐1978 birth cohorts could capture 55% of F0‐F3 individuals. Under the 80% linked‐to‐care scenario, screening limited in 1968‐1978 birth cohorts could sustain treatment at levels required to achieve the HCV elimination goals. Conclusion In Italy, which is an HCV endemic country, the eligible pool of patients to treat will run out between 2025 and 2028. To maintain the treatment rate and achieve the HCV elimination goals, increased case finding in targeted, high prevalence groups is required.

Published
2018

15. Targeted next‐generation sequencing of adult gliomas for retrospective prognostic evaluation and up‐front diagnostics

Author

Petersen, J. K., primary, Boldt, H. B., additional, Sørensen, M. D., additional, Blach, S., additional, Dahlrot, R. H., additional, Hansen, S., additional, Burton, M., additional, Thomassen, M., additional, Kruse, T., additional, Poulsen, F. R., additional, Andreasen, L., additional, Hager, H., additional, Ulhøi, B. P., additional, Lukacova, S., additional, Reifenberger, G., additional, and Kristensen, B. W., additional

Published
2020
Full Text
View/download PDF

17. PITER collaborating group. Forecasting Hepatitis C liver disease burden on real life data. Does the hidden iceberg matter to reach the elimination goals?

Author

Kondili, La, Robbins, S, Blach, S, Gamkrelidze, I, Zignego, Al, Brunetto, Mr, Raimondo, G, Taliani, G, Iannone, A, Russo, Fp, Santantonio, Ta, Zuin, M, Chessa, L, Blanc, P, Puoti, M, Vinci, M, Erne, Em, Strazzabosco, M, Massari, M, Lampertico, P, Rumi, Mg, Federico, A, Orlandini, A, Ciancio, A, Borgia, G, Andreone, P, Caporaso, N, Persico, M, Ieluzzi, D, Madonia, S, Gori, A, Gasbarrini, A, Coppola, C, Brancaccio, G, Andriulli, A, Quaranta, Mg, Montilla, S, Razavi, H, Melazzini, M, Vella, S, and Craxì, A

Published
2018

18. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study

Author

Razavi-Shearer, D. Gamkrelidze, I. Nguyen, M.H. Chen, D.-S. Van Damme, P. Abbas, Z. Abdulla, M. Abou Rached, A. Adda, D. Aho, I. Akarca, U. Al Ali, F.H. Lawati, F.A.L. Naamani, K.A.L. Alashgar, H.I. Alavian, S.M. Alawadhi, S. Albillos, A. Al-Busafi, S.A. Aleman, S. Alfaleh, F.Z. Aljumah, A.A. Anand, A.C. Anh, N.T. Arends, J.E. Arkkila, P. Athanasakis, K. Bane, A. Ben-Ari, Z. Berg, T. Bizri, A.R. Blach, S. Brandão Mello, C.E. Brandon, S.M. Bright, B. Bruggmann, P. Brunetto, M. Buti, M. Chan, H.L.Y. Chaudhry, A. Chien, R.-N. Choi, M.S. Christensen, P.B. Chuang, W.-L. Chulanov, V. Clausen, M.R. Colombo, M. Cornberg, M. Cowie, B. Craxi, A. Croes, E.A. Cuellar, D.A. Cunningham, C. Desalegn, H. Drazilova, S. Duberg, A.-S. Egeonu, S.S. El-Sayed, M.H. Estes, C. Falconer, K. Ferraz, M.L.G. Ferreira, P.R. Flisiak, R. Frankova, S. Gaeta, G.B. García-Samaniego, J. Genov, J. Gerstoft, J. Goldis, A. Gountas, I. Gray, R. Guimarães Pessôa, M. Hajarizadeh, B. Hatzakis, A. Hézode, C. Himatt, S.M. Hoepelman, A. Hrstic, I. Hui, Y.-T.T. Husa, P. Jahis, R. Janjua, N.Z. Jarcuška, P. Jaroszewicz, J. Kaymakoglu, S. Kershenobich, D. Kondili, L.A. Konysbekova, A. Krajden, M. Kristian, P. Laleman, W. Lao, W.-C.C. Layden, J. Lazarus, J.V. Lee, M.-H. Liakina, V. Lim, Y.-S.S. Loo, C.-K.K. Lukšic, B. Malekzadeh, R. Malu, A.O. Mamatkulov, A. Manns, M. Marinho, R.T. Maticic, M. Mauss, S. Memon, M.S. Mendes Correa, M.C. Mendez-Sanchez, N. Merat, S. Metwally, A.M. Mohamed, R. Mokhbat, J.E. Moreno, C. Mossong, J. Mourad, F.H. Müllhaupt, B. Murphy, K. Musabaev, E. Nawaz, A. Nde, H.M. Negro, F. Nersesov, A. Nguyen, V.T.T. Njouom, R. Ntagirabiri, R. Nurmatov, Z. Obekpa, S. Ocama, P. Oguche, S. Omede, O. Omuemu, C. Opare-Sem, O. Opio, C.K. Örmeci, N. Papatheodoridis, G. Pasini, K. Pimenov, N. Poustchi, H. Quang, T.D. Qureshi, H. Ramji, A. Razavi-Shearer, K. Redae, B. Reesink, H.W. Rios, C.Y. Rjaskova, G. Robbins, S. Roberts, L.R. Roberts, S.K. Ryder, S.D. Safadi, R. Sagalova, O. Salupere, R. Sanai, F.M. Sanchez-Avila, J.F. Saraswat, V. Sarrazin, C. Schmelzer, J.D. Schréter, I. Scott, J. Seguin-Devaux, C. Shah, S.R. Sharara, A.I. Sharma, M. Shiha, G.E. Shin, T. Sievert, W. Sperl, J. Stärkel, P. Stedman, C. Sypsa, V. Tacke, F. Tan, S.S. Tanaka, J. Tomasiewicz, K. Urbanek, P. van der Meer, A.J. Van Vlierberghe, H. Vella, S. Vince, A. Waheed, Y. Waked, I. Walsh, N. Weis, N. Wong, V.W. Woodring, J. Yaghi, C. Yang, H.-I. Yang, C.-L. Yesmembetov, K. Yosry, A. Yuen, M.-F. Yusuf, M.A.M. Zeuzem, S. Razavi, H. The Polaris Observatory Collaborators

Abstract

Background: The 69th World Health Assembly approved the Global Health Sector Strategy to eliminate viral hepatitis by 2030. Although no virological cure exists for hepatitis B virus (HBV) infection, existing therapies to control viral replication and prophylaxis to minimise mother-to-child transmission make elimination of HBV feasible. We aimed to estimate the national, regional, and global prevalence of HBsAg in the general population and in the population aged 5 years in 2016, as well as coverage of prophylaxis, diagnosis, and treatment. Methods: In this modelling study, we used a Delphi process that included a literature review in PubMed and Embase, followed by interviews with experts, to quantify the historical epidemiology of HBV infection. We then used a dynamic HBV transmission and progression model to estimate the country-level and regional-level prevalence of HBsAg in 2016 and the effect of prophylaxis and treatment on disease burden. Findings: We developed models for 120 countries, 78 of which were populated with data approved by experts. Using these models, we estimated that the global prevalence of HBsAg in 2016 was 3·9% (95% uncertainty interval [UI] 3·4–4·6), corresponding to 291 992 000 (251 513 000–341 114 000) infections. Of these infections, around 29 million (10%) were diagnosed, and only 4·8 million (5%) of 94 million individuals eligible for treatment actually received antiviral therapy. Around 1·8 (1·6–2·2) million infections were in children aged 5 years, with a prevalence of 1·4% (1·2–1·6). We estimated that 87% of infants had received the three-dose HBV vaccination in the first year of life, 46% had received timely birth-dose vaccination, and 13% had received hepatitis B immunoglobulin along with the full vaccination regimen. Less than 1% of mothers with a high viral load had received antiviral therapy to reduce mother-to-child transmission. Interpretation: Our estimate of HBV prevalence in 2016 differs from previous studies, potentially because we took into account the effect of infant prophylaxis and early childhood vaccination, as well as changing prevalence over time. Although some regions are well on their way to meeting prophylaxis and prevalence targets, all regions must substantially scale-up access to diagnosis and treatment to meet the global targets. Funding: John C Martin Foundation. © 2018 Elsevier Ltd

Published
2018

20. Targeted next‐generation sequencing of adult gliomas for retrospective prognostic evaluation and up‐front diagnostics.

Author

Petersen, J. K., Boldt, H. B., Sørensen, M. D., Blach, S., Dahlrot, R. H., Hansen, S., Burton, M., Thomassen, M., Kruse, T., Poulsen, F. R., Andreasen, L., Hager, H., Ulhøi, B. P., Lukacova, S., Reifenberger, G., and Kristensen, B. W.

Subjects
NUCLEOTIDE sequencing, ASTROCYTOMAS, GLIOMAS, ISOCITRATE dehydrogenase, CENTRAL nervous system, ADULTS
Abstract

Aims: We aimed to reclassify a population‐based cohort of 529 adult glioma patients to evaluate the prognostic impact of the 2016 World Health Organization (WHO) central nervous system tumour classification. Moreover, we evaluated the feasibility of gene panel next‐generation sequencing (NGS) in daily diagnostics of 225 prospective glioma patients. Methods: The retrospective cohort was reclassified according to WHO 2016 criteria by immunohistochemistry for IDH‐R132H, fluorescence in situ hybridization for 1p/19q‐codeletion and gene panel NGS. All tumours of the prospective cohort were subjected to NGS analysis up‐front. Results: The entire population‐based cohort was successfully reclassified according to WHO 2016 criteria. NGS results were obtained for 98% of the prospective patients. Survival analyses in the population‐based cohort confirmed three major prognostic subgroups, that is, isocitrate dehydrogenase (IDH)‐mutant and 1p/19q‐codeleted oligodendrogliomas, IDH‐mutant astrocytomas and IDH‐wildtype glioblastomas. The distinction between WHO grade II and III was prognostic in patients with IDH‐mutant astrocytoma. The survival of patients with IDH‐wildtype diffuse astrocytomas carrying TERT promoter mutation and/or EGFR amplification overlapped with the poor survival of IDH‐wildtype glioblastoma patients. Conclusions: Gene panel NGS proved feasible in daily diagnostics. In addition, our study confirms the prognostic role of glioma classification according to WHO 2016 in a large population‐based cohort. Molecular features of glioblastoma in IDH‐wildtype diffuse glioma were linked to poor survival corresponding to IDH‐wildtype glioblastoma patients. The distinction between WHO grade II and III retained prognostic significance in patients with IDH‐mutant diffuse astrocytic gliomas. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

21. The present and future disease burden of hepatitis C virus infections with today's treatment paradigm

Author

Chan, H. L. Y., Chen, C. J., Omede, O., Al Qamish, J., Al Naamani, K., Bane, A., Tan, S. S., Simonova, M., Cardenas, I., Derbala, M., Akin, O., Phillips, R. O., Abdelmageed, M. K., Abdulla, M., Adda, D., Al Baqali, A., Al Dweik, N., Al Ejji, K., Al ghazzawi, I., Al Kaabi, S., Al Sadadi, M., Al Salman, J., AlBadri, M., Al-Busafi, S. A., Al-Romaihi, H. E., Ampofo, W., Antonov, K., Anyaike, C., Arome, F., Blach, S., Borodo, M. M., Brandon, S. M., Bright, B., Butt, M. T., Chen, D. S., Chen, P. J., Chien, R. N., Chuang, W. L., Cuellar, D., Elbardiny, A. A., Estes, C., Farag, E., Fung, J., Gamkrelidze, I., Garcia, V., Genov, J., Ghandour, Z., Ghuloom, M., Gomez, B., Gunter, J., Habeeb, J., Hajelssedig, O., Hamoudi, W., Himatt, S. M., Hrstic, I., Hu, C. C., Huang, C. F., Hui, Y. T., Jahis, R., Jelev, D., John, A. K., Kaliaskarova, K. S., Kamel, Y., Kao, J. H., Khamis, J., Khattabi, H., Khoudri, I., Konysbekova, A., Kotzev, I., Lai, M. S., Lao, W. C., Layden, J., Lee, M. H., Lesi, O., Li, M., Lo, A., Loo, C. K., Lukšić, B., Maaroufi, A., Malu, A. O., Mateva, L., Mitova, R., Mohamed, R., Morović, M., Murphy, K., Mustapha, B., Nersesov, A., Ngige, E., Njouom, R., Njoya, O., Nonković, D., Obekpa, S., Oguche, S., Okolo, E. E., Omuemu, C., Ondoa, P., Opare- Sem, O., Owusu-Ofori, S., Prokopenko, Y. N., Razavi, H., Razavi-Shearer, D., Razavi-Shearer, K., Redae, B., Reic, T., Rinke de Wit, T., Rios, C., Robbins, S., Roberts, L. R., Sanad, S. J., Schmelzer, J. D., Sharma, M., Su, T. H., Sultan, K., Tchernev, K., Tsang, O. T. Y., Tsang, S., Tzeuton, C., Ugoeze, S., Uzochukwu, B., Vi, R., Vince, A., Wani, H. U., Wong, V. W. S., Workneh, A., Yacoub, R., Yesmembetov, K. I., Youbi, M., Yuen, M. F., and Nde, H.

Subjects
parasitic diseases, hepatitis C, incidence, mortality, prevalence, treatment, geographic locations
Abstract

Factors influencing the morbidity and mortality associated with viremic hepatitis C virus (HCV) infection change over time and place, making it difficult to compare reported estimates. Models were developed for 17 countries (Bahrain, Bulgaria, Cameroon, Colombia, Croatia, Dominican Republic, Ethiopia, Ghana, Hong Kong, Jordan, Kazakhstan, Malaysia, Morocco, Nigeria, Qatar and Taiwan) to quantify and characterize the viremic population as well as forecast the changes in the infected population and the corresponding disease burden from 2015 to 2030. Model inputs were agreed upon through expert consensus, and a standardized methodology was followed to allow for comparison across countries. The viremic prevalence is expected to remain constant or decline in all but four countries (Ethiopia, Ghana, Jordan and Oman) ; however, HCV-related morbidity and mortality will increase in all countries except Qatar and Taiwan. In Qatar, the high-treatment rate will contribute to a reduction in total cases and HCV- related morbidity by 2030. In the remaining countries, however, the current treatment paradigm will be insufficient to achieve large reductions in HCV- related morbidity and mortality.

Published
2017

22. Strategies to manage hepatitis C virus infection disease burden

Author

Chen, D. S., Hamoudi, W., Mustapha, B., Layden, J., Nersesov, A., Reic, T., Garcia, V., Rios, C., Mateva, L., Njoya, O., Al-Busafi, S. A., Abdelmageed, M. K., Abdulla, M., Adda, D., Akin, O., Al Baqali, A., Al Dweik, N., Al Ejji, K., Al ghazzawi, I., Al Kaabi, S., Al Naamani, K., Al Qamish, J., Al Sadadi, M., Al Salman, J., AlBadri, M., Al-Romaihi, H. E., Ampofo, W., Antonov, K., Anyaike, C., Arome, F., Bane, A., Blach, S., Borodo, M. M., Brandon, S. M., Bright, B., Butt, M. T., Cardenas, I., Chan, H. L. Y., Chen, C. J., Chen, P. J., Chien, R. N., Chuang, W. L., Cuellar, D., Derbala, M., Elbardiny, A. A., Estes, C., Farag, E., Fung, J., Gamkrelidze, I., Genov, J., Ghandour, Z., Ghuloom, M., Gomez, B., Gunter, J., Habeeb, J., Hajelssedig, O., Himatt, S. M., Hrstic, I., Hu, C. C., Huang, C. F., Hui, Y. T., Jahis, R., Jelev, D., John, A. K., Kaliaskarova, K. S., Kamel, Y., Kao, J. H., Khamis, J., Khattabi, H., Khoudri, I., Konysbekova, A., Kotzev, I., Lai, M. S., Lao, W. C., Lee, M. H., Lesi, O., Li, M., Lo, A., Loo, C. K., Lukšić, B., Maaroufi, A., Malu, A. O., Mitova, R., Mohamed, R., Morović, M., Murphy, K., Nde, H., Ngige, E., Njouom, R., Nonković, D., Obekpa, S., Oguche, S., Okolo, E. E., Omede, O., Omuemu, C., Ondoa, P., Opare-Sem, O., Owusu-Ofori, S., Phillips, R. O., Prokopenko, Y. N., Razavi, H., Razavi-Shearer, D., Razavi-Shearer, K., Redae, B., Rinke de Wit, T., Robbins, S., Roberts, L. R., Sanad, S. J., Sharma, M., Simonova, M., Su, T. H., Sultan, K., Tan, S. S., Tchernev, K., Tsang, O. T. Y., Tsang, S., Tzeuton, C., Ugoeze, S., Uzochukwu, B., Vi, R., Vince, A., Wani, H. U., Wong, V. W. S., Workneh, A., Yacoub, R., Yesmembetov, K. I., Youbi, M., Yuen, M. F., and Schmelzer, J. D.

Subjects
diagnosis, disease burden, elimination, epidemiology, hepatitis C, scenarios, strategy
Abstract

The hepatitis C virus (HCV) epidemic was forecasted through 2030 for 17 countries in Africa, Asia, Europe, Latin America and the Middle East, and interventions for achieving the Global Health Sector Strategy on viral hepatitis targets —“WHO Targets” (65% reduction in HCV-related deaths, 90% reduction in new infections and 90% of infections diagnosed by 2030) were considered. Scaling up treatment and diagnosis rates over time would be required to achieve these targets in all but one country, even with the introduction of high SVR therapies. The scenarios developed to achieve the WHO Targets in all countries studied assumed the implementation of national policies to prevent new infections and to diagnose current infections through screening.

Published
2017

23. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study

Author

Blach, S. Zeuzem, S. Manns, M. Altraif, I. Duberg, A.-S. Muljono, D.H. Waked, I. Alavian, S.M. Lee, M.-H. Negro, F. Abaalkhail, F. Abdou, A. Abdulla, M. Abou Rached, A. Aho, I. Akarca, U. Al Ghazzawi, I. Al Kaabi, S. Al Lawati, F. Al Namaani, K. Al Serkal, Y. Al-Busafi, S.A. Al-Dabal, L. Aleman, S. Alghamdi, A.S. Aljumah, A.A. Al-Romaihi, H.E. Andersson, M.I. Arendt, V. Arkkila, P. Assiri, A.M. Baatarkhuu, O. Bane, A. Ben-Ari, Z. Bergin, C. Bessone, F. Bihl, F. Bizri, A.R. Blachier, M. Blasco, A.J. Brandao Mello, C.E. Bruggmann, P. Brunton, C.R. Calinas, F. Chan, H.L.Y. Chaudhry, A. Cheinquer, H. Chen, C.-J. Chien, R.-N. Choi, M.S. Christensen, P.B. Chuang, W.-L. Chulanov, V. Cisneros, L. Clausen, M.R. Cramp, M.E. Craxi, A. Croes, E.A. Dalgard, O. Daruich, J.R. De Ledinghen, V. Dore, G.J. El-Sayed, M.H. Ergor, G. Esmat, G. Estes, C. Falconer, K. Farag, E. Ferraz, M.L.G. Ferreira, P.R. Flisiak, R. Frankova, S. Gamkrelidze, I. Gane, E. Garcia-Samaniego, J. Khan, A.G. Gountas, I. Goldis, A. Gottfredsson, M. Grebely, J. Gschwantler, M. Guimaraes Pessoa, M. Gunter, J. Hajarizadeh, B. Hajelssedig, O. Hamid, S. Hamoudi, W. Hatzakis, A. Himatt, S.M. Hofer, H. Hrstic, I. Hui, Y.-T. Hunyady, B. Idilman, R. Jafri, W. Jahis, R. Janjua, N.Z. Jarčuška, P. Jeruma, A. Jonasson, J.G. Kamel, Y. Kao, J.-H. Kaymakoglu, S. Kershenobich, D. Khamis, J. Kim, Y.S. Kondili, L. Koutoubi, Z. Krajden, M. Krarup, H. Lai, M.-S. Laleman, W. Lao, W.-C. Lavanchy, D. Lazaro, P. Leleu, H. Lesi, O. Lesmana, L.A. Li, M. Liakina, V. Lim, Y.-S. Luksic, B. Mahomed, A. Maimets, M. Makara, M. Malu, A.O. Marinho, R.T. Marotta, P. Mauss, S. Memon, M.S. Mendes Correa, M.C. Mendez-Sanchez, N. Merat, S. Metwally, A.M. Mohamed, R. Moreno, C. Mourad, F.H. Mullhaupt, B. Murphy, K. Nde, H. Njouom, R. Nonkovic, D. Norris, S. Obekpa, S. Oguche, S. Olafsson, S. Oltman, M. Omede, O. Omuemu, C. Opare-Sem, O. Ovrehus, A.L.H. Owusu-Ofori, S. Oyunsuren, T.S. Papatheodoridis, G. Pasini, K. Peltekian, K.M. Phillips, R.O. Pimenov, N. Poustchi, H. Prabdial-Sing, N. Qureshi, H. Ramji, A. Razavi-Shearer, D. Razavi-Shearer, K. Redae, B. Reesink, H.W. Ridruejo, E. Robbins, S. Roberts, L.R. Roberts, S.K. Rosenberg, W.M. Roudot-Thoraval, F. Ryder, S.D. Safadi, R. Sagalova, O. Salupere, R. Sanai, F.M. Sanchez Avila, J.F. Saraswat, V. Sarmento-Castro, R. Sarrazin, C. Schmelzer, J.D. Schreter, I. Seguin-Devaux, C. Shah, S.R. Sharara, A.I. Sharma, M. Shevaldin, A. Shiha, G.E. Sievert, W. Sonderup, M. Souliotis, K. Speiciene, D. Sperl, J. Starkel, P. Stauber, R.E. Stedman, C. Struck, D. Su, T.-H. Sypsa, V. Tan, S.-S. Tanaka, J. Thompson, A.J. Tolmane, I. Tomasiewicz, K. Valantinas, J. Van Damme, P. Van Der Meer, A.J. Van Thiel, I. Van Vlierberghe, H. Vince, A. Vogel, W. Wedemeyer, H. Weis, N. Wong, V.W.S. Yaghi, C. Yosry, A. Yuen, M.-F. Yunihastuti, E. Yusuf, A. Zuckerman, E. Razavi, H. The Polaris Observatory HCV Collaborators

Abstract

Background The 69th World Health Assembly approved the Global Health Sector Strategy to eliminate hepatitis C virus (HCV) infection by 2030, which can become a reality with the recent launch of direct acting antiviral therapies. Reliable disease burden estimates are required for national strategies. This analysis estimates the global prevalence of viraemic HCV at the end of 2015, an update of—and expansion on—the 2014 analysis, which reported 80 million (95% CI 64–103) viraemic infections in 2013. Methods We developed country-level disease burden models following a systematic review of HCV prevalence (number of studies, n=6754) and genotype (n=11 342) studies published after 2013. A Delphi process was used to gain country expert consensus and validate inputs. Published estimates alone were used for countries where expert panel meetings could not be scheduled. Global prevalence was estimated using regional averages for countries without data. Findings Models were built for 100 countries, 59 of which were approved by country experts, with the remaining 41 estimated using published data alone. The remaining countries had insufficient data to create a model. The global prevalence of viraemic HCV is estimated to be 1·0% (95% uncertainty interval 0·8–1·1) in 2015, corresponding to 71·1 million (62·5–79·4) viraemic infections. Genotypes 1 and 3 were the most common cause of infections (44% and 25%, respectively). Interpretation The global estimate of viraemic infections is lower than previous estimates, largely due to more recent (lower) prevalence estimates in Africa. Additionally, increased mortality due to liver-related causes and an ageing population may have contributed to a reduction in infections. Funding John C Martin Foundation. © 2017 Elsevier Ltd

Published
2017

25. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study

Author

Razavi, H. Robbins, S. Zeuzem, S. Negro, F. Buti, M. Duberg, A. Roudot-Thoraval, F. Craxi, A. Manns, M. Marinho, R.T. Hunyady, B. Colombo, M. Aleman, S. Antonov, K. Arkkila, P. Athanasakis, K. Blach, S. Blachier, M. Blasco, A.J. Calinas, F. Calleja, J.L. Christensen, P.B. Cramp, M.E. Croes, E. de Knegt, R.J. de Ledinghen, V. Delile, J.-M. Estes, C. Falconer, K. Färkkilä, M. Flisiak, R. Frankova, S. Gamkrelidze, I. García-Samaniego, J. Genov, J. Gerstoft, J. Gheorghe, L. Goldis, A. Gountas, I. Gregorčič, S. Gschwantler, M. Gunter, J. Halota, W. Harcouet, L. Hézode, C. Hoffmann, P. Horvath, G. Hrstic, I. Jarčuška, P. Jelev, D. Jeruma, A. Kåberg, M. Kieran, J. Kondili, L.A. Kotzev, I. Krarup, H. Kristian, P. Lagging, M. Laleman, W. Lázaro, P. Liakina, V. Lukšić, B. Maimets, M. Makara, M. Mateva, L. Maticic, M. Mennini, F.S. Mitova, R. Moreno, C. Mossong, J. Murphy, K. Nde, H. Nemecek, V. Nonkovic, D. Norris, S. Oltman, M. Øvrehus, A.L.H. Papatheodoridis, G. Pasini, K. Razavi-Shearer, D. Razavi-Shearer, K. Reesink, H.W. Reic, T. Rozentale, B. Ryder, S.D. Salupere, R. Sarmento-Castro, R. Sarrazin, C. Schmelzer, J.D. Schréter, I. Seguin-Devaux, C. Simojoki, K. Simonova, M. Smit, P.J. Souliotis, K. Speiciene, D. Sperl, J. Stärkel, P. Struck, D. Sypsa, V. Thornton, L. Tolmane, I. Tomasiewicz, K. Valantinas, J. Van Damme, P. van de Vijver, D. van der Meer, A.J. van Santen, D. Van Vlierberghe, H. Vandijck, D. Vella, S. Videčnik-Zorman, J. Vogel, W. Weis, N. Hatzakis, A. The European Union HCV Collaborators

Abstract

Background Hepatitis C virus (HCV) is a leading cause of liver-related morbidity and mortality worldwide. In the European Union (EU), treatment and cure of HCV with direct-acting antiviral therapies began in 2014. WHO targets are to achieve a 65% reduction in liver-related deaths, a 90% reduction of new viral hepatitis infections, and 90% of patients with viral hepatitis infections being diagnosed by 2030. This study assessed the prevalence of HCV in the EU and the level of intervention required to achieve WHO targets for HCV elimination. Methods We populated country Markov models for the 28 EU countries through a literature search of PubMed and Embase between Jan 1, 2000, and March 31, 2016, and a Delphi process to gain expert consensus and validate inputs. We aggregated country models to create a regional EU model. We used the EU model to forecast HCV disease progression (considering the effect of immigration) and developed a strategy to acehive WHO targets. We used weighted average sustained viral response rates and fibrosis restrictions to model the effect of current therapeutic guidelines. We used the EU model to forecast HCV disease progression (considering the effect of immigration) under current screening and therapeutic guidelines. Additionally, we back-calculated the total number of patients needing to be screened and treated to achieve WHO targets. Findings We estimated the number of viraemic HCV infections in 2015 to be 3 238 000 (95% uncertainty interval [UI] 2 106 000–3 795 000) of a total population of 509 868 000 in the EU, equating to a prevalence of viraemic HCV of 0·64% (95% UI 0·41–0·74). We estimated that 1 180 000 (95% UI 1 003 000–1 357 000) people were diagnosed with viraemia (36·4%), 150 000 (12 000–180 000) were treated (4·6% of the total infected population or 12·7% of the diagnosed population), 133 000 (106 000–160 000) were cured (4·1%), and 57 900 (43 900–67 300) were newly infected (1·8%) in 2015. Additionally, 30 400 (26 600–42 500) HCV-positive immigrants entered the EU. To achieve WHO targets, unrestricted treatment needs to increase from 150 000 patients in 2015 to 187 000 patients in 2025 and diagnosis needs to increase from 88 800 new cases annually in 2015 to 180 000 in 2025. Interpretation Given its advanced health-care infrastructure, the EU is uniquely poised to eliminate HCV; however, expansion of screening programmes is essential to increase treatment to achieve the WHO targets. A united effort, grounded in sound epidemiological evidence, will also be necessary. Funding Gilead Sciences. © 2017 Elsevier Ltd

Published
2017

26. Disease Burden of Hepatitis C in the Austrian state of Tyrol – Epidemiological Data and Model Analysis to achieve Elimination by 2030

Author

Schaefer, B, additional, Viveiros, A, additional, Al-Zoairy, R, additional, Blach, S, additional, Brandon, S, additional, Razavi, H, additional, Dorn, L, additional, Finkenstedt, A, additional, Effenberger, M, additional, Graziadei, I, additional, Sarcletti, M, additional, Tilg, H, additional, and Zoller, H, additional

Published
2018
Full Text
View/download PDF

33. Forecasting liver disease burden based on a real life cohort of the linked to care patients in Italy. Does the ‘underwater portion of the iceberg’ matter to reach the WHO HCV eliminating goals in the high HCV prevalent countries?

Author

Robbins, S., primary, Kondili, L., additional, Blach, S., additional, Gamkrelidze, I., additional, Zignego, A., additional, Brunetto, M., additional, Raimondo, G., additional, Taliani, G., additional, Iannone, A., additional, Russo, F.P., additional, Santantonio, T.A., additional, Zuin, M.G., additional, Chessa, L., additional, Blanc, P., additional, Puoti, M., additional, Vinci, M., additional, Erne, E.M., additional, Strazzabosco, M., additional, Massari, M., additional, Lampertico, P., additional, Rumi, M.G., additional, Federico, A., additional, Ferrari, C., additional, Ciancio, A., additional, Borgia, G., additional, Andreone, P., additional, Caporaso, N., additional, Persico, M., additional, Ieluzzi, D., additional, Gori, A., additional, Gasbarrini, A., additional, Coppola, C., additional, Gaeta, G.B., additional, Andriulli, A., additional, Montilla, S., additional, Razavi, H., additional, Melazzini, M., additional, Vella, S., additional, and Craxi, A., additional

Published
2018
Full Text
View/download PDF

34. Forecasting liver disease burden

Author

Robbins, S., primary, Kondili, L.A., additional, Blach, S., additional, Gamkrelidze, I., additional, Zignego, A.L., additional, Brunetto, M.R., additional, Raimondo, G., additional, Taliani, G., additional, Iannone, A., additional, Russo, F.P., additional, Santantonio, T., additional, Zuin, M., additional, Chessa, L., additional, Blanc, P.L., additional, Puoti, M., additional, Vinci, M., additional, Erne, E.M., additional, Strazzabosco, M., additional, Massari, M., additional, Lampertico, P., additional, Rumi, M.G., additional, Federico, A., additional, Ferrari, C., additional, Ciancio, A., additional, Borgia, G., additional, Andreone, P., additional, Caporaso, N., additional, Persico, M., additional, Ieluzzi, D., additional, Gori, A., additional, Gasbarrini, A., additional, Coppola, C., additional, Madonia, S., additional, Gaeta, G.B., additional, Andriulli, A., additional, Montilla, S., additional, Razavi, H., additional, Melazzini, M., additional, Vella, S., additional, and Craxi, A., additional

Published
2018
Full Text
View/download PDF

36. The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2

Author

Hatzakis, A. Chulanov, V. Gadano, A. C. Bergin, C. and Ben-Ari, Z. Mossong, J. Schreter, I. Baatarkhuu, O. and Acharya, S. Aho, I. Anand, A. C. Andersson, M. I. and Arendt, V. Arkkila, P. Barclay, K. Bessone, F. Blach, S. and Blokhina, N. Brunton, C. R. Choudhuri, G. Cisneros, L. and Croes, E. A. Dahgwahdorj, Y. A. Dalgard, O. Daruich, J. R. Dashdorj, N. R. Davaadorj, D. de Knegt, R. J. de Vree, M. Estes, C. Flisiak, R. Gane, E. Gower, E. and Halota, W. Henderson, C. Hoffmann, P. Hornell, J. and Houlihan, D. Hrusovsky, S. Jarcuska, P. Kershenobich, D. and Kostrzewska, K. Kristian, P. Leshno, M. Lurie, Y. and Mahomed, A. Mamonova, N. Mendez-Sanchez, N. Norris, S. and Nurmukhametova, E. Nymadawa, P. Oltman, M. Oyunbileg, J. and Oyunsuren, Ts. Papatheodoridis, G. Pimenov, N. and Prabdial-Sing, N. Prins, M. Radke, S. Rakhmanova, A. and Razavi-Shearer, K. Reesink, H. W. Ridruejo, E. Safadi, R. and Sagalova, O. Sanchez Avila, J. F. Sanduijav, R. and Saraswat, V. Seguin-Devaux, C. Shah, S. R. Shestakova, I. and Shevaldin, A. Shibolet, O. Silva, M. O. Sokolov, S. and Sonderup, M. Souliotis, K. Spearman, C. W. Staub, T. and Stedman, C. Strebkova, E. A. Struck, D. Sypsa, V. and Tomasiewicz, K. Undram, L. van der Meer, A. J. van Santen, D. Veldhuijzen, I. Villamil, F. G. Willemse, S. and Zuckerman, E. Zuure, F. R. Puri, P. Razavi, H.

Abstract

Morbidity and mortality attributable to chronic hepatitis C virus (HCV) infection are increasing in many countries as the infected population ages. Models were developed for 15 countries to quantify and characterize the viremic population, as well as estimate the number of new infections and HCV related deaths from 2013 to 2030. Expert consensus was used to determine current treatment levels and outcomes in each country. In most countries, viremic prevalence has already peaked. In every country studied, prevalence begins to decline before 2030, when current treatment levels were held constant. In contrast, cases of advanced liver disease and liver related deaths will continue to increase through 2030 in most countries. The current treatment paradigm is inadequate if large reductions in HCV related morbidity and mortality are to be achieved.

Published
2015

37. Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2

Author

Saraswat, V. Norris, S. de Knegt, R. J. Sanchez Avila, J. F. and Sonderup, M. Zuckerman, E. Arkkila, P. Stedman, C. and Acharya, S. Aho, I. Anand, A. C. Andersson, M. I. and Arendt, V. Baatarkhuu, O. Barclay, K. Ben-Ari, Z. and Bergin, C. Bessone, F. Blach, S. Blokhina, N. Brunton, C. R. Choudhuri, G. Chulanov, V. Cisneros, L. Croes, E. A. Dahgwahdorj, Y. A. Dalgard, O. Daruich, J. R. and Dashdorj, N. R. Davaadorj, D. de Vree, M. Estes, C. and Flisiak, R. Gadano, A. C. Gane, E. Halota, W. Hatzakis, A. Henderson, C. Hoffmann, P. Hornell, J. Houlihan, D. and Hrusovsky, S. Jarcuska, P. Kershenobich, D. Kostrzewska, K. Kristian, P. Leshno, M. Lurie, Y. Mahomed, A. and Mamonova, N. Mendez-Sanchez, N. Mossong, J. Nurmukhametova, E. Nymadawa, P. Oltman, M. Oyunbileg, J. Oyunsuren, Ts. and Papatheodoridis, G. Pimenov, N. Prabdial-Sing, N. Prins, M. Puri, P. Radke, S. Rakhmanova, A. Razavi, H. and Razavi-Shearer, K. Reesink, H. W. Ridruejo, E. Safadi, R. and Sagalova, O. Sanduijav, R. Schreter, I. Seguin-Devaux, C. Shah, S. R. Shestakova, I. Shevaldin, A. Shibolet, O. and Sokolov, S. Souliotis, K. Spearman, C. W. Staub, T. and Strebkova, E. A. Struck, D. Tomasiewicz, K. Undram, L. and van der Meer, A. J. van Santen, D. Veldhuijzen, I. Villamil, F. G. Willemse, S. Zuure, F. R. Silva, M. O. Sypsa, V. and Gower, E.

Abstract

Chronic hepatitis C virus (HCV) infection is a leading cause of liver related morbidity and mortality. In many countries, there is a lack of comprehensive epidemiological data that are crucial in implementing disease control measures as new treatment options become available. Published literature, unpublished data and expert consensus were used to determine key parameters, including prevalence, viremia, genotype and the number of patients diagnosed and treated. In this study of 15 countries, viremic prevalence ranged from 0.13% in the Netherlands to 2.91% in Russia. The largest viremic populations were in India (8666000 cases) and Russia (4162000 cases). In most countries, males had a higher rate of infections, likely due to higher rates of injection drug use (IDU). Estimates characterizing the infected population are critical to focus screening and treatment efforts as new therapeutic options become available.

Published
2015

38. Strategies to manage hepatitis C virus (HCV) infection disease burden - volume 2

Author

Gane, E. Kershenobich, D. Seguin-Devaux, C. Kristian, P. and Aho, I. Dalgard, O. Shestakova, I. Nymadawa, P. Blach, S. Acharya, S. Anand, A. C. Andersson, M. I. Arendt, V. and Arkkila, P. Baatarkhuu, O. Barclay, K. Ben-Ari, Z. and Bergin, C. Bessone, F. Blokhina, N. Brunton, C. R. and Choudhuri, G. Chulanov, V. Cisneros, L. Croes, E. A. and Dahgwahdorj, Y. A. Daruich, J. R. Dashdorj, N. R. Davaadorj, D. de Knegt, R. J. de Vree, M. Gadano, A. C. Gower, E. and Halota, W. Hatzakis, A. Henderson, C. Hoffmann, P. and Hornell, J. Houlihan, D. Hrusovsky, S. Jarcuska, P. and Kostrzewska, K. Leshno, M. Lurie, Y. Mahomed, A. and Mamonova, N. Mendez-Sanchez, N. Mossong, J. Norris, S. and Nurmukhametova, E. Oltman, M. Oyunbileg, J. Oyunsuren, Ts. and Papatheodoridis, G. Pimenov, N. Prins, M. Puri, P. and Radke, S. Rakhmanova, A. Razavi, H. Razavi-Shearer, K. and Reesink, H. W. Ridruejo, E. Safadi, R. Sagalova, O. and Sanchez Avila, J. F. Sanduijav, R. Saraswat, V. Schreter, I. and Shah, S. R. Shevaldin, A. Shibolet, O. Silva, M. O. and Sokolov, S. Sonderup, M. Souliotis, K. Spearman, C. W. and Staub, T. Stedman, C. Strebkova, E. A. Struck, D. Sypsa, V. Tomasiewicz, K. Undram, L. van der Meer, A. J. van Santen, D. Veldhuijzen, I. Villamil, F. G. Willemse, S. and Zuckerman, E. Zuure, F. R. Prabdial-Sing, N. Flisiak, R. and Estes, C.

Abstract

The hepatitis C virus (HCV) epidemic was forecasted through 2030 for 15 countries, and the relative impact of two scenarios was considered: (i) increased treatment efficacy while holding the treated population constant and (ii) increased treatment efficacy and increased annual treated population. Increasing levels of diagnosis and treatment, in combination with improved treatment efficacy, were critical for achieving substantial reductions in disease burden. In most countries, the annual treated population had to increase several fold to achieve the largest reductions in HCV-related morbidity and mortality. This suggests that increased capacity for screening and treatment will be critical in many countries. Birth cohort screening is a helpful tool for maximizing resources. In most of the studied countries, the majority of patients were born between 1945 and 1985.

Published
2015

45. THU-059 - Forecasting liver disease burden based on a real life cohort of the linked to care patients in Italy. Does the ‘underwater portion of the iceberg’ matter to reach the WHO HCV eliminating goals in the high HCV prevalent countries?

Author

Robbins, S., Kondili, L., Blach, S., Gamkrelidze, I., Zignego, A., Brunetto, M., Raimondo, G., Taliani, G., Iannone, A., Russo, F.P., Santantonio, T.A., Zuin, M.G., Chessa, L., Blanc, P., Puoti, M., Vinci, M., Erne, E.M., Strazzabosco, M., Massari, M., Lampertico, P., Rumi, M.G., Federico, A., Ferrari, C., Ciancio, A., Borgia, G., Andreone, P., Caporaso, N., Persico, M., Ieluzzi, D., Gori, A., Gasbarrini, A., Coppola, C., Gaeta, G.B., Andriulli, A., Montilla, S., Razavi, H., Melazzini, M., Vella, S., and Craxi, A.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results